Construction and validation of a three-gene prognostic model based on mitochondrial RNA modification co-expression signatures in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a severe global health burden. Mitochondrial RNA modification (MRM) may contribute to tumor development by altering mitochondrial activity. We investigated whether gene-expression features related to MRM could be used to generate an HCC prognostic signature and characterize its association with the tumor immune microenvironment. Public training and validation cohorts, together with MRM-related genes (MRM-RGs), were retrieved. Differentially expressed genes (DEGs) were identified, and MRM-coexpressed DEGs were obtained by intersecting DEGs with key module genes selected by WGCNA. Prognostic candidates were filtered through stepwise analyses before risk-model establishment, validation, independent prognostic assessment, and nomogram construction. Differences between the high- and low-risk groups were examined, including prognostic-gene expression and proinflammatory factor patterns. qRT-PCR and immunohistochemistry were then used to verify prognostic gene expression, and clinical associations were analyzed. A three-gene signature (GHR, ADRA1A, DBH) was identified. The risk score independently predicted survival, together with T stage; the nomogram showed acceptable calibration and moderate discrimination. High-risk patients displayed enriched proliferative pathways, increased M0 macrophages and regulatory T cells (Tregs), higher TIDE and exclusion scores, and upregulated IL-1β/IL-1α. Low expression of these genes in HCC was confirmed, and was associated with high alpha-fetoprotein (AFP), poor differentiation, and advanced tumor stage. Significant correlations with multiple MRM-related genes were observed. This three-gene signature, derived from MRM-associated co-expression patterns, was associated with HCC prognosis and may provide a potential reference for patient stratification and immunotherapy-related research; however, these findings are correlative and require further validation.
Authors
- 高英堂
- Chenxuan Wu (ORCID: https://orcid.org/0009-0007-9576-153X)
- Tao Han (ORCID: https://orcid.org/0000-0003-4216-6968)
- Yue Qi (ORCID: https://orcid.org/0009-0002-4710-1944)
Institutions
- Tianjin Third Central Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1007/s12672-026-06276-3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00